Cardiff Oncology's Onvansertib Combo Associated With Two-Fold Increase Disease Control Rate In Prostate Cancer Study

Cardiff Oncology Inc (NASDAQ: CRDF) has announced updated data from its Phase 2 trial evaluating the oral combination of onvansertib, Johnson & Johnson's JNJ Zytiga (abiraterone), and prednisone for metastatic castrate-resistant prostate cancer (mCRPC). Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium.
Updated data showed that increasing the number of days of treatment with onvansertib from 5 to 14 in a 21-day cycle was associated with a greater than a two-fold increase (29% to 63%) in disease control rate at 12 weeks, the trial's primary efficacy endpoint.
Six of eight (75%) evaluable patients had stable disease upon radiographic scan at 12 weeks, and five of these patients remain on treatment to-date.
Circulating tumor DNA (ctDNA) analysis revealed differences in baseline genomic profiles of patients achieving SD at 12 weeks vs. those progressing at or before 12 weeks.
Mutations present exclusively in patients with stable disease at 12 weeks were associated with cell cycle and DNA repair pathways that may increase the onvansertib-abiraterone combination efficiency.
On the safety front, a combination of onvansertib and abiraterone is well tolerated across the three different dosing schedules.
Price Action: CRDF stock increased 10.3% at $14.35 during market trading hours on the last check Thursday.